Amid a continuing debate over healthcare spending in the United States, the oncology community is growing more introspective about the costs associated with increasingly sophisticated cancer therapeutics.
J. Russell Hoverman, MD, PhD
Advertisement
Articles by J. Russell Hoverman, MD, PhD
Advertisement
Latest Updated Articles
Ranking Value in Cancer Care: Analysis of a "Pathways" ApproachAugust 13th 2012
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
5